A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells

Clinical Cancer Research

Volumn 17, Issue 21, 2011, Pages 6733-6741

  Miyamoto, Shingo ^a   Iwamoto, Ryo ^c   Furuya, Akiko ^d   Takahashi, Kumiko ^d   Sasaki, Yuka ^d   Ando, Hiroshi ^d   Yotsumoto, Fusanori ^a   Yoneda, Tomoko ^c   Hamaoka, Miki ^c   Yagi, Hiroshi ^b   Murakami, Takuya ^d   Hori, Sayaka ^d   Shitara, Kenya ^d   Mekada, Eisuke ^c  

^a FUKUOKA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC MONOCLONAL ANTIBODY KM3566; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KM3566; MONOCLONAL ANTIBODY KM3579; MONOCLONAL ANTIBODY MAB259; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; CERCOPITHECUS AETHIOPS; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, SCID; OVARIAN NEOPLASMS; SUBSTRATE SPECIFICITY; VERO CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80455140254     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1029     Document Type: Article

References (26)

1. American Cancer Society. Cancer facts and figures 2010. Atlanta: American Cancer Society; 2010.
2. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 1991;251:936-9. (Pubitemid 21926188)
3. Goishi K, Higashiyama S, Klagsbrun M, Nakano N, Umata T, Ishikawa M, et al. Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity. Mol Biol Cell 1995;6:967-80.
4. Yamazaki S, Iwamoto R, Saeki K, Asakura M, Takashima S, Yamazaki A, et al. Mice with defects in HB-EGF ectodomain shedding show severe developmental abnormalities. J Cell Biol 2003;163:469-75. (Pubitemid 37429861)
5. Mekada E, Iwamoto R. UCSD Nature molecule pages 2008; doi: 10.1038/mp.a002932.01.
6. Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H, et al. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 2004;64:5720-7. (Pubitemid 39095570)
7. Tanaka Y, Miyamoto S, Suzuki SO, Oki E, Yagi H, Sonoda K, et al. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res 2005;11:4783-92. (Pubitemid 41557199)
8. Naef M, Yokoyama M, Friess H, Buchler MW, Korc M. Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma. Int J Cancer 1996;66:315-21. (Pubitemid 26166192)
9. Murayama Y, Miyagawa J, Shinomura Y, Kanayama S, Isozaki K, Yamamori K, et al. Significance of the association between haparin-binding epidermal growth factor-like growth factor and CD9 in human gastric cancer. Int J Cancer 2002;98:505-13. (Pubitemid 34208550)
10. Ito Y, Takeda T, Higashiyama S, Noguchi S, Matsuura N. Expression of heparin-binding epidermal growth factor-like growth factor in breast carcinoma. Breast Cancer Res Treat 2001;67:81-5. (Pubitemid 32703391)
11. Suo Z, Risberg B, Karlsson MG, Villman K, Skovlund E, Nesland JM. The expression of EGFR family ligands in breast carcinomas. Int J Surg Pathol 2002;10:91-9. (Pubitemid 34655095)
12. Revillion F, Lhotellier V, Hornez L, Bonneterre J, Payrat JP. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol 2008;19:73-80.
13. Yagi H, Yotsumoto F, Sonoda K, Kuroki M, Mekada E, Miyamoto S. Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer. Int J Cancer 2009;124:1429-39.
14. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc gamma receptor FcRIIIa gene. Blood 2002;99:754-8. (Pubitemid 34525533)
15. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789-96.
16. Yoshida H, Shitara S. Generation and characterization of monoclonal antibodies to recombinant human granulocyte-colony stimulating factor (G-CSF) and its muteins. Agric Biol Chem 1989;53:1095-101.
17. Iwamoto R, Yamasaki S, Asakura M, Takashima S, Hasuwa H, Miyado K, et al. Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci USA 2003;100:3221-6. (Pubitemid 36356564)
18. Iwamoto R, Handa K, Mekada E. Contact-dependent growth inhibition and apoptosis of epidermal growth factor (EGF) receptor-expressing cells by the membrane-anchored form of heparin-binding EGF-like growth factor. J Biol Chem 1999;274:25906-12.
19. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 2004;87:614-22. (Pubitemid 39295406)
20. Hamaoka M, Chinen I, Murata T, Takashima S, Iwamoto R, Mekada E. Anti-human HB-EGF monoclonal antibodies inhibiting ectodomain shedding of HB-EGF and diphtheria toxin binding. J Biochem 2010;148:55-69.
21. Nakamura K, Tanaka Y, Fujino I, Hirayama N, Shitara K, Hanai N. Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody. Mol Immunol 2000;37:1035-46. (Pubitemid 32786716)
22. Yotsumoto F, Yagi H, Suzuki SO, Oki E, Tsujioka H, Hachisuga T, et al. Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun 2008;365:555-61. (Pubitemid 350181687)
23. Lindzen M, Lavi S, Leitner O, Yarden Y. Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands. Proc Natl Acad Sci USA 2010;107:12559-63.
24. Shishido Y, Sharma KD, Higashiyama S, Klagsbrun M, Mekada E. Heparin-like molecules on the cell surface potentiate binding of diphtheria toxin to the diphtheria toxin receptor/membrane-anchored heparin-binding epidermal growth factor-like growth factor. J Biol Chem 1995;270:29578-85.
25. Iwamoto R, Mine N, Kawaguchi T, Minami S, Saeki K, Mekada E. HB-EGF function in cardiac valve development requires interaction with heparan sulfate proteoglycans. Development 2010;137:2205-14.
26. Nakamura K, Iwamoto R, Mekada E. Membrane-anchored heparin-binding EGF-like growth factor (HB-EGF) and diphtheria toxin receptor-associated protein (DRAP27)/CD9 form a complex with integrin a3b1 at cell-cell contact sites. J Cell Biol 1995;129:1691-705.